Table 4.
Exposure to proton pump inhibitors before baseline | |||||
Any exposure | 1 d - 2.8 y | >2.8–4.4 y | >4.4 y | ||
(n = 1,481) | (n = 451) | (n = 459) | (n = 571) | ||
Outcome: incident dementia | |||||
# of dementia events | 165 | 53 | 48 | 64 | |
Exposure to H2RAs (ref) before baseline | Any exposure | 0.97 (0.70–1.35) | |||
1 d–2.8 y | 0.80 (0.39–1.64) | ||||
>2.8–4.4 y | 1.01 (0.53–1.93) | ||||
>4.4 y | 1.02 (0.61–1.70) |
Abbreviations: APOE = Apolipoprotein E4; H2RA = H2 receptor antagonist.
All results are hazard ratios (95% CIs).
We calculated person-years of follow-up as time elapsed from the baseline date (visit 5) to whichever came first: dementia event, loss to follow-up, death, or administratively censored at December 2017.
Adjusted for age, sex, race, education, BMI, APOE4, hypertension, diabetes, stroke, and aspirin use.
H2RAs are the reference group for each analysis.